Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
March 30, 2020 16:07 ET
|
Equillium
LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 26, 2020 16:07 ET
|
Equillium
EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
December 12, 2019 07:00 ET
|
Equillium; Biocon Ltd
LA JOLLA, Calif. and BENGALURU, India, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop...
Equillium Granted U.S. FDA Fast Track Designation for Itolizumab for the Treatment of Lupus Nephritis
December 09, 2019 16:10 ET
|
Equillium
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Featured in Panel Discussion at Capital Markets Day for Kidney Health
November 15, 2019 08:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Reports Third Quarter 2019 Financial Results and Recent Highlights
November 12, 2019 16:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium to Present at Investor Conferences in November 2019
November 07, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019
November 06, 2019 08:05 ET
|
Equillium
LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update
October 01, 2019 16:05 ET
|
Equillium
Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC Company receives exclusive rights to negotiate licensing rights to develop and commercialize itolizumab...
Equillium to Host Business Update Call on October 1, 2019
September 17, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat...